Table 3.
Summary of studies.
| Study/Year | Country† | HA/HB‡ | Ped/Adult§ | MHD assessment tool¶ | MHD prevalence n/total (%) | Comorbidities n/total (%)†† |
|---|---|---|---|---|---|---|
|
| ||||||
| Spencer 1968 | US | NR | P/A | Psychiatric evaluation | Depression 3/26 (12%) Anxiety 0/26 (0%) |
NR |
| Klein 1982 | US | NR | Ped | BDI | Depression 3/11 (27%) | NR |
| Dew 1990 | US | NR | A | SCL90 | Depression 32/75 (44%) Anxiety 25/75 (33%) |
HIV 31/75 (41%) |
| Burton 1991 | US | AB | Ped | CDI | Depression 12/22 (55%) Anxiety 9/22 (41%) |
HIV 5/27 (19%) |
| Catalan 1992 | UK | HA | NR | PSE / Catego | Depression 2/73 (3%) Anxiety 3/73 (4%) |
HIV 37/73 (51%) |
| Riedel 1992 | Germany | HA | NR | PDS | Depression 28/209 (13%) | HIV 181/209 (87%) |
| Bussing 1993 | US | AB | Ped | K-SADS | Anxiety 9/23 (39%) | HIV 6/23 (26%) |
| Mayes 1996 | US | AB | Ped | Psychiatric evaluation | ADHD 19/66 (29%) | HIV 18/66 (27%) |
| Thompson 1996 | UK | AB | Ped | CAPA | Depression 1/64 (2%) Anxiety 1/64 (2%) ADHD 1/64 (2%) |
HIV 31/64 (48%) |
| Miners 1999 | UK | AB | A | EQ-5D | Anxiety/Depression 54/166 (33%) | HIV 31/168 (18%) |
| Celiker 2000 | Turkey | AB | Ped | CDI | Depression 2/12 (17%) | Arthritis 12/12 (100%) |
| Shapiro 2001 | US | HA | Ped | Self-report | ADHD 13/131 (10%) | NR |
| Sadowski 2003 | Int. | HA | Ped | K-SADS | Depression 7/58 (12%) Anxiety 7/58 (12%) ADHD 3/58 (5%) |
HIV 7/58 (12%) Arthritis 23/58 (40%) |
| Woodrich 2003 | US | AB | Ped | ADHD-IV scale | ADHD 11/34 (32%) | NR |
| Bahls 2006 | Brazil | NR | Ped | CDI | Depression 7/20 (35%) | NR |
| Ghanizadeh 2009 | Iran | AB | Ped | K-SADS | Depression 5/83 (6%) Anxiety 4/83 (5%) |
HCV 15/83 (18%) HBV 1/83 (1%) |
| Siboni 2009 | Italy | AB | A | GDS-30 | Depression 18/39 (46%) | HIV 5/39 (13%) HCV 36/38 (95%) HBV 4/38 (11%) Arthritis 37/39 (95%) |
| Spencer 2009 | US | AB | Ped | ADHD-IV scale | ADHD 5/18 (28%) | NR |
| Hasan 2011 | Egypt | HA | Ped | BDI | Depression 34/50 (68%) | NR |
| Khleif 2011 | US | AB | A | Medical record review | Depression 5/63 (8%) | HIV 16/63 (25%) HCV 49/63 (78%) HBV 4/63 (6%) Arthritis 33/63 (52%) |
| Iannone 2012 | US | AB | A | PHQ-9 | Depression 15/41 (37%) | HIV 13/41 (32%) HCV 23/41 (56%) Arthritis 10/41 (24%) |
| Abali 2014 | Turkey | HA | Ped | SCARED | Anxiety 16/42 (38%) | NR |
| Kodra 2014 | Italy | AB | P/A | EQ-5D | Anxiety/Depression 28/73 (38%) | NR |
| Ozelo 2015 | Int. | A | P/A | EQ-5D | Anxiety/Depression 46/150 (31%) | HIV 14/150 (9%) |
| Buckner 2016 | US | HB | A | EQ-5D, PHQ-9, GAD-7 Self-report | Depression 66/299 (22%) Anxiety 70/299 (23%) Anxiety/Depression 105/243 (43%) |
HIV 27/299 (9%) HCV 15/299 (5%) Arthritis 144/299 (48%) |
| Hu 2017 | China | HA | NR | CHO-KLAT | Anxiety 4/22 (18%) | NR |
| Sun 2017 | Int. | AB | A | EQ-5D, self-report | Depression 88/675 (13%) Anxiety 97/675 (14%) Anxiety / Depression 313/675 (46%) |
HIV 121/675 (18%) HCV 289/675 (43%) Arthritis 325/675 (48%) |
| Kempton 2018 | US | AB | A | EQ-5D, self-report | Depression 73/381 (19%) Anxiety 53/381 (14%) Anxiety/Depression 165/381 (43%) |
Arthritis 246/381 (65%) |
Int.- international, UK- United Kingdom, US- United States
HA- haemophilia A, HB- haemophilia B, AB - haemophilia A and B
A- Adults, Ped- Pediatries, P/A- Pediatries and Adults
MHD- mental health disorder, BDI- Beck Depression Inventory, CAPA- Child and Adolescent Psychiatric Assessment, CDI- Children’s Depression Inventory, CHO-KLAT- Canadian Hemophilia Outcomes- Kids’ Life Assessment Tool, EQ-5D- EuroQoL five dimension scale, GAD-7- General Anxiety Disorder 7, GDS-30- Geriatric Depression Scale 30, K-SADS- Schedule for Affective Disorders and Schizophrenia for School-Aged Children, PDS- Paranoid-Depression Scale, PHQ 9- Patient Health Questionnaire 9, PSE- Present State Examination, SCARED- Screen for Child Anxiety Related Disorders, SCL90- Symptoms Checklist 90; ADHD- attention deficit hyperactivity disorder
HBV- hepatitis B virus, HCV- hepatitis C virus, HIV- human immunodeficiency virus, NR- not reported.